Erratum: Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR) (Clin Infect Dis (2015) 61 (800-806) DOI: 10.1093/cid/civ495);Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)

Clinical Infectious Diseases

Volumn 61, Issue 5, 2015, Pages 800-806

  Evans, Scott R ^a   Rubin, Daniel ^b   Follmann, Dean ^c   Pennello, Gene ^d   Huskins, W Charles ^e   Powers, John H ^f,g   Schoenfeld, David ^h   Chuang Stein, Christy ⁱ   Cosgrove, Sara E ^j   Fowler, Vance G ^k   Lautenbach, Ebbing ^l   Chambers, Henry F ^m  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^e MAYO CLINIC   (United States)

^f GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ PFIZER INC   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k DUKE UNIVERSITY   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Antibiotic use strategies; DOOR; RADAR

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DESIRABILITY OF OUTCOME RANKING; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESPONSE ADJUSTED FOR DURATION OF ANTIBIOTIC RISK; RISK BENEFIT ANALYSIS; SAMPLE SIZE; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS; PATIENT SAFETY; RISK; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, BACTERIAL; HUMANS; PATIENT SAFETY; RESEARCH DESIGN; RISK; TREATMENT OUTCOME;

EID: 84942023902     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciac352     Document Type: Erratum

References (14)

1. Cosgrove SE, Seo SK, Bolon MK, et al. Evaluation of post-prescription review and feedback as a method of promoting rational antimicrobial use: a multicenter intervention. Infect Control Hosp Epidemiol 2012; 33:374-80.
2. Peron EP, Hirsch AA, Jury LA, Jump RL, Donskey CJ. Another setting for stewardship: high rate of unnecessary antimicrobial use in a Veterans Affairs long-term care facility. J Am Geriatr Soc 2013; 61:289-90.
3. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38(suppl 4):S341-5.
4. Rice LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol 2009; 12:476-81.
5. Snappin SM. Noninferiority trials. Curr Control Trials Cardiovasc Med 2000; 1:19-21.
6. Powers JH, Cooper CK, Lin D, Ross DB. Sample size and the ethics of non-inferiority trials. Lancet 2005; 366:24-5.
7. Fleming TR. Current issues in non-inferiority trials. Stat Med 2008; 27:317-32.
8. Powers JH. Noninferiority and equivalence trials: deciphering "similarity" of medical interventions. Stat Med 2008; 27:343-52.
9. Evans S. Noninferiority clinical trials. Chance 2009; 22:53-8.
10. Li Y, He Y, Sheng Y, et al. Systematic evaluation of non-inferiority and equivalence randomized trials of anti-infective drugs. Expert Rev Anti Infect Ther 2013; 11:1377-89.
11. Oczkowski SJ. A clinician's guide to the assessment and interpretation of noninferiority trials for novel therapies. Open Med 2014; 8:e67-372.
12. Djulbegovic B, Clarke M. Scientific and ethical issues in equivalence trials. JAMA 2001; 285:1206-8.
13. Noether GE. Sample-size determination for some common nonparametric tests. J Am Stat Assoc 1987; 82:645-7.
14. Chambers HF, Bartlett JG, Bonomo RA, et al. Antibacterial resistance leadership group: open for business. Clin Infect Dis 2014; 58:1571-6.